Table 1 Patients` characteristics
Characteristic | Number of patients absolute relative | |
|---|---|---|
Sex | ||
 Female | 11 | 39.3% |
 Male | 17 | 60.7% |
Karnofsky performance status (KPS) | ||
 90–100% | 22 | 78.6% |
 80% | 5 | 17.9% |
 70% | 1 | 3.6% |
BRAF Status | ||
 BRAF V600-E-Mutation | 14 | 50.0% |
 No BRAF V600-E-Mutation | 14 | 50.0% |
Controlled extracranial disease | ||
 Yes | 10 | 35.7% |
 No | 18 | 64.3% |
RPA class | ||
 1 | 6 | 21.4% |
 2 | 22 | 78.6% |
 3 | 0 | 0% |
Melanoma-molGPA | ||
 0.5–1.0 | 2 | 7.1% |
 1.5–2.0 | 11 | 39.3% |
 2.5–3.0 | 11 | 39.3% |
 3.5–4.0 | 4 | 14.3% |
Number of SRS lesions per patient | ||
 1 | 13 | 46.4% |
 2 | 7 | 25.0% |
 3 | 7 | 25.0% |
 4 | 1 | 3.6% |
Whole brain radiotherapy | ||
 Yes | 4 | 14.3% |
Before first SRS | 1 | 3.6% |
After first SRS | 3 | 10.7% |
 No | 24 | 85.7% |
Targeted/ immunotherapy (TT/IT) | ||
 BRAFi (Dabrafenib/ Vemurafenib)  MEKi (Trametinib) | 2 1 | 7.1% 3.6% |
 Anti-CTLA-4 (Ipilimumab) | 2 | 7.1% |
 Anti-PD1 (Nivolumab/Pembrolizumab) | 6 | 21.4% |
 BRAFi+MEKi (Dabrafenib-Trametinib/ Encorafenib-Binimetinib) | 3 | 10.7% |
 BRAFi+MEKi ➔ Anti-PD1 | 1 | 3.6% |
 Anti-PD1 + Anti-CTLA-4 (Nivolumab-Ipilimumab) | 7 | 25.0% |
 BRAFi+MEKi ➔Triple combination (Pembrolizumab-Dabrafenib-Trametinib) | 1 | 3.6% |
none | 5 | 17.9% |
Concurrent TT/IT | ||
 Yes | 20 | 71.4% |
 No | 8 | 28.6% |